In particular, the combination with anti-VEGF antibodies led to significant reductions in ascites and peritoneal disease burden, leading to prolonged survival in tumor-bearing mice compared to mice treated with the bispecific monotherapy or the anti-PD-1 combination. This evidence concerns the gene VEGFA and neoplasm.